Europe is arming itself with two new treatments to fight the Coronavirus. The European Medicines Agency (EMA) on Thursday approved the monoclonal antibody treatment of GlaxoSmithKline as well as an immunosuppressive drug already authorized in the EU for various inflammatory conditions.
GSK “is intended for the treatment of Covid-19 in adults and adolescents who do not need supplemental oxygen and who are at increased risk of the severity of the disease,” the EMA said in a statement, while the use of the Kineret has been “extended to the treatment of Covid-19 in adult patients (…) who need supplemental oxygen (…) and who are at risk of developing severe respiratory failure”.